The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease
Open accessAbstract
Interactions of the presynaptic proteins, neuronal pentraxin 2 (NPTX2) and neurexin 2α (NRXN22α), with their respective postsynaptic functional partners, GluA4‐containing glutamate (AMPA4) receptor and neuroligin 1 (NLGN1), enhance excitatory synaptic activity in some areas of the hippocampus and cerebral cortex. As early damage of such excitatory circuits in the brain tissues of participants with Alzheimer's disease (AD) correlates with cognitive losses, plasma neuron‐derived exosome (NDE) levels of these 2 pairs of specialized synaptic proteins were quantified to assess their biomarker characteristics. The NDE contents of all 4 proteins were decreased significantly in AD dementia ( n = 46), and diminished levels of AMPA4 and NLGN1 correlated with the extent of cognitive loss. In a preclinical period, 6–11 yr before the onset of dementia, the NDE levels of all but NPTX2 were significantly lower than those of matched controls, and levels of all proteins declined significantly with the development of dementia. Reductions in NDE levels of these specialized excitatory synaptic proteins may therefore be indicative of the extent of cognitive loss and may reflect progression of the severity of AD.—Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., Schwartz, J. B. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. FASEB J. 32, 888–893 (2018). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study on plasma neuronal exosomes of patients with AD dementia revealed declined levels of NPTX2 compared with matched controls.”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Goetzl et al. 2018
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Neuroligins and neurexins link synaptic function to cognitive disease
Südhof, T. C. (2008) · Nature · doi:10.1038/nature07456 · Cited by 1,849 · cited 1×
“Presynaptic neurexin2a (NRXN2a) and the postsynaptic adhesion protein, neuroligin1 (NLGN1), interact trans-synaptically to ensure structural stability and functions of excitatory synapses in the hippocampus and cortex (6, 7).”
BackgroundMustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441
Self-citationDecreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600816r · Cited by 398
Self-citationCargo proteins of plasma astrocyte‐derived exosomes in Alzheimer's disease
Goetzl, E. J., Mustapic, M., Kapogiannis, D., Eitan, E., Lobach, I. V., Goetzl, L., Schwartz, J. B., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600756r · Cited by 386
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
Kapogiannis, D., Boxer, A. L., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U. B., Frassetto, L. A., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2014) · The FASEB Journal · doi:10.1096/fj.14-262048 · Cited by 345
Self-citationNarp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., Sutula, T. P., McBain, C. J., & Worley, P. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2621 · Cited by 316
NPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316
Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00463-x · Cited by 265
Pelkey, K. A., Barksdale, E., Craig, M. T., Yuan, X., Sukumaran, M., Vargish, G. A., Mitchell, R. M., Wyeth, M. S., Petralia, R. S., Chittajallu, R., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.020 · Cited by 245
Cano, S., Posner, H. B., Moline, M. L., Hurt, S. W., Swartz, J., Hsu, T., & Hobart, J. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204008 · Cited by 208
Clare, R., King, V. G., Wirenfeldt, M., & Vinters, H. V. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22392 · Cited by 163
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146
Soler-Llavina, G. J., Fuccillo, M. V., Ko, J., Südhof, T. C., & Malenka, R. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114028108 · Cited by 145
Guekht, A. B., Skoog, I. G., Korczyn, A. D., Zakharov, V. V., Eeg, M., & Vigonius, U. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000357122 · Cited by 113
Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency
Bie, B., Wu, J., Yang, H., Xu, J. J., Brown, D. L., & Naguib, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3618 · Cited by 105
Brito-Moreira, J., Lourenco, M. V., Oliveira, M. M., Ribeiro, F. C., Ledo, J. H., Diniz, L. P., Vital, J. F. S., Magdesian, M. H., Melo, H. M., Barros-Aragão, F., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761189 · Cited by 84
Dinamarca, M. C., Luca, M. D., Godoy, J. A., & Inestrosa, N. C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.107 · Cited by 32
A truncating mutation in Alzheimer's disease inactivates neuroligin-1 synaptic function
Tristán‐Clavijo, E., Camacho-Garcia, R. J., Robles-Lanuza, E., Ruiz, A., van der Zee, J., Broeckhoven, C. V., Hernandez, I., Martínez-Mir, A., & Scholl, F. G. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.004 · Cited by 30
Pelkey, K. A., Barksdale, E., Craig, M. T., Yuan, X., Sukumaran, M., Vargish, G. A., Mitchell, R. M., Wyeth, M. S., Petralia, R. S., Chittajallu, R., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.024 · Cited by 22
Flagged first, then by citations
Cited by
Sorted by citations
Circulating Extracellular Vesicles in Human Disease
Shah, R. V., Patel, T. C., & Freedman, J. E. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1704286 · Cited by 765
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503
Extracellular Vesicles and Neurodegenerative Diseases
Hill, A. F. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0147-18.2019 · Cited by 437
High complement levels in astrocyte‐derived exosomes of Alzheimer disease
Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D. (2018) · Annals of Neurology · doi:10.1002/ana.25172 · Cited by 373
Self-citation
Metadata
- Authors
- Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B.
- Affiliations
- University of California, San Francisco (US)
- University of Kentucky (US)
- National Institute on Aging (US)
- Corresponding author
- Goetzl, Edward J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2018-01-04
- Volume
- 32
- Issue
- 2
- Pages
- 888-893
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC5888398
- OpenAlex
- W2761598264
- Cited by
- 219
- References
- 28
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 29 · 2023: 27 · 2022: 38 · 2021: 30 · 2020: 21 · 2019: 26 · 2018: 12
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG028383)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, plasma biomarkers, NPTX2, neuroligin-1, excitatory synapses, cognitive decline, disease progression, preclinical Alzheimer's disease, synaptic proteins
- MeSH terms
- Pentraxins, Aged, Alzheimer Disease, C-Reactive Protein, Female, Humans, Male, Nerve Tissue Proteins, Neurons, Synaptic Membranes, Cell Adhesion Molecules, Neuronal, Receptors, AMPA, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
